Krakow, Poland – 16 October 2019 – Ryvu Therapeutics and Selvita today announced that following approvals from the National Depository for Securities (“KDPW”) and the Warsaw Stock Exchange (“GPW”), Selvita will be from now on listed on the Warsaw Stock Exchange under the symbol SLV.
Ryvu Therapeutics will continue to be publicly listed under the symbol RVU.
Selvita is an integrated service company providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development. The company was established in 2007 and currently employs almost 450 scientists. Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland and foreign offices located in Cambridge, MA and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK.
The company provides integrated drug discovery support from hit identification, through lead selection, lead optimization, and nomination of a preclinical candidate. On top of that, Selvita provides world-class pharma services in the field of drug testing and bioanalytical analyses, offering services at every stage of the drug discovery process, from development and validation of methods, stability studies, to routine quality control testing. Significant portion of Selvita business is also dedicated to a broad range of chemistry research and development activities, particularly for the pharma and agrochemical companies. Selvita laboratories are both GLP and GMP certified. Selvita is a major shareholder in Ardigen, a provider of precision medicine and artificial intelligence services.
Piotr Ksiazek (investors and media)
+48 501 988 693
Natalia Baranowska (corporate)
+48 784 069 418